CELLTRION WILL SUPPLY ITS COVID-19 TREATMENT WITHOUT PROFIT MARGIN IN S. KOREA

Highlights –

• Celltrion will supply its COVID-19 treatment without profit margin in S. Korea.
• Celltrion’s CT-P59 began to be supplied to local medical institutions on Wednesday.
• The company has also planned to supply the treatmen...

CELLTRION’S COVID-19 ANTIBODY TREATMENT CONFIRMED TO NEUTRALIZE VIRUS VARIANT

Highlights –

• Celltrion’s COVID-19 antibody treatment confirmed to neutralize virus variant.
• The company’s CT-P59, an anti-COVID-19 monoclonal antibody treatment neutralized the British virus variant.
• The company has also t...

JAPAN’S KOBAYASHI KAKO CO. RECEIVES AN ORDER TO SUSPEND BUSINESS FOR 116 DAYS

Highlights –

• Japan’s Kobayashi Kako Co. receives an order to suspend business for 116 days.
• The company was guilty of making fictitious production records on nearly 80 percent of its products.
• The company last year had recalled ...

TAKEDA AIMS TO GO PUBLIC IN THE NEXT 5 TO 10 YEARS AFTER BLACKSTONE’S ACQUISITION

Highlights –

• Takeda Pharmaceutical aims to go public in the next 5 to 10 years after Blackstone’s acquisition.
• The unit needs to expand its business overseas in Chinese-speaking markets.
• Takeda plans to sell its drug unit to Bl...

TAKEDA PHARMACEUTICAL CO.RAISED ITS NET PROFIT OUTLOOK FOR THIS YEAR

Highlights –

• Takeda pharmaceutical co. raised its net profit outlook for this year.
• The drug-making company revised its bottom-line outlook to $880 million.
• It also reported an operating profit outlook to $374 million.
• Tak...

LONDON – LISTED SHARES ROSE ON WEDNESDAY

Highlights –

• London-listed shares rose on Wednesday.
• Pharmaceutical companies saw the most gains.
• The blue-chip FTSE 100 .FTSE was up 1.0%.
• Online fashion retailer ASOS (ASOS.L) shares jumped by 2.8%.

On ...

WALL STREET INVESTORS ARE LIKELY TO SHIFT TO LARGE PHARMACEUTICAL COMPANIES

Highlights –

• Wall Street investors are likely to shift to large pharmaceutical companies.
• Investors are moving away from their investment from small biotech firms.
• Big pharma companies are racing over production of COVID-19 vaccines.<...

Cipla drops 5 percent as a result of fears against Goa unit

The Indian multinational biotechnology and pharmaceutical company-Cipla has dropped to 5% in Friday’s session. The dive is attributed to extensive changes by Capital market company-Equirius, which said the unit will have to meet the changes as per the USFDA guidelines. 
News sou...